April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Molecular features of interaction between VEGF-A and anti-angiogenic molecules
Author Affiliations & Notes
  • Chiara B M Platania
    Clinical and Molecular Biomedicine, Pharmacology and Biochemistry, University of Catania, Catania, Italy
  • Salvatore Salomone
    Clinical and Molecular Biomedicine, Pharmacology and Biochemistry, University of Catania, Catania, Italy
  • Filippo Drago
    Clinical and Molecular Biomedicine, Pharmacology and Biochemistry, University of Catania, Catania, Italy
  • Claudio Bucolo
    Clinical and Molecular Biomedicine, Pharmacology and Biochemistry, University of Catania, Catania, Italy
  • Footnotes
    Commercial Relationships Chiara B M Platania, None; Salvatore Salomone, None; Filippo Drago, None; Claudio Bucolo, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1943. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chiara B M Platania, Salvatore Salomone, Filippo Drago, Claudio Bucolo; Molecular features of interaction between VEGF-A and anti-angiogenic molecules. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1943. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To identify the molecular features of well characterized anti-VEGFA (bevacizumab, ranibizumab and aflibercept) as a reference guide to design new effective anti-angiogenic molecules.

 
Methods
 

We carried out the molecular modeling of aflibercept binding domain (R1D2_R2D3), characterized by the fusion of domain D2 of VEGFR1 and domain D3 of VEGFR2, by means of SwissModel web server using as template the crystal structure of VEGFR2 (PDB: 2X1W). All-atom molecular dynamics of R1D2_R2D3 in explicit water was carried out for 10 ns. Three protein-protein docking software were used (ZDock, GRAMMX and Pydock) in order to carry out docking of VEGFA with bevacizumab, ranibizumab and modeled aflibercept binding domains.

 
Results
 

The protein-protein docking gave consistent results for ranibizumab and bevacizumab in complex with VEGF-A in comparison to the correspondent crystal structures, respectively 1CZ8 and 1BJ1. Since the docking protocol was successful for ranibizumab and bevacizumab, modeling of VEGF-A interaction with modeled R1D2_R2D3 was carried out. Interactions of R1D2_R2D3 in complex with VEGF-A resembled the binding of VEGF-C with VEGFR2 (Fig. 1). Pydock had a prediction rate comparable to the other software hereby used, in addition pydock output was informative of binding energy terms: electrostatic (ELEC), desolvation (DES), Van Der Waals (VDW), total docking score (TOT). Interestingly the binding of VEGF-A to ranibizumab and bevacizumab was characterized by different stabilizing energy terms, in comparison to aflibercept binding domain (table1).

 
Conclusions
 

Molecular modeling approaches are feasible to evaluate binding features of VEGF in complex with anti-angiogenic factors, and might help to design new anti-VEGF drugs with better inhibitory effects.

 
 
Figure 1. Comparison between R1D2_R2D3/VEGF-A and VEGFR2/VEGF-C complexes.
 
Figure 1. Comparison between R1D2_R2D3/VEGF-A and VEGFR2/VEGF-C complexes.
 
 
Table 1. Pydock energy terms: (Elect= electrostatic), (DES= desolvation), (VDW=Van der Waals), (TOT= total docking score).
 
Table 1. Pydock energy terms: (Elect= electrostatic), (DES= desolvation), (VDW=Van der Waals), (TOT= total docking score).
 
Keywords: 473 computational modeling • 543 growth factors/growth factor receptors  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×